Kinser, Robin D.

From: Nelson, Bettie L
Sent: Tuesday, November 27, 2001 9:09 AM
To: Kinser, Robin D.
Subject: BIOMARKER QUESTIONS

Message Flag: Follow up
Flag Status: Flagged

Robin,

There are some biomarker measures that are reporting below the limit of detection. Do you have any thoughts as to how such values should be handled in the analyses?

I spoke with Hans who suggested that nicotine should be the most important variable to consider in determining the sample size. Is there a biomarker or some priority of biomarkers that should be considered as we examine the data to determine whether more than one sample should be taken? In addition to nicotine can you prioritize the biomarkers that should be considered in the determination of sample size?

With best regards,

Bettie

Clinical Testing/SA
PM/USA
P.O. Box 26603
Richmond, VA 23261
Tel: (804) 274-1502
Fax (804) 274-3982
e-mail: Bettie.L.Nelson@pmusa.com

PM3001172257

Source: https://www.industrydocuments.ucsf.edu/docs/xzfk0001